Webinar: Digital Subtraction Angiography With Significantly Reduced Radiation Dose

Imaging Technology News Webinar Series — Supported by an educational grant from Philips Healthcare

 

January 10, 2014
Presenter Michael Soderman, M.D., Ph.D.
This webinar explains novel noise reduction technology for digital subtraction angiography and how this reduces radiation dose and affects image quality. The presenter is Michael Soderman, M.D., Ph.D., chief neuroangiography, Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
 
The webinar took place Feb. 13, 2014. To view the archived version, register for this webinar.
 
This webinar is part of the Imaging Technology News Webinar Series — supported by an educational grant from Philips Healthcare.
 
Statement of Purpose/Need:
This webinar will explain novel noise reduction technology for digital subtraction angiography and how this reduces radiation dose and affects image quality.
 
Learning Objectives:
Upon completion of this activity, participants will be able to:
• Identify the working principle of dose reduction algorithms.
• Apply strategies to reduce radiation doses in digital subtraction angiography and fluoroscopy
• Summarize how the software may affect image quality
 
Intended Audience:
This webinar is intended for radiologists, interventional radiologists and neurologists involved in neuro-angiographic imaging. 
 
Presenter:
Michael Soderman, M.D., Ph.D., 
Senior consultant, Chief Neuroangiography and stereotaxy, Department of Neuroradiology, 
Karolinska University Hospital, Stockholm, Sweden
Associate Professor, Karolinska Institute, Stockholm, Sweden
 
Disclosure Information:
Current guidelines require that participants in CME/CE activities be made aware of all affiliations or financial interests that may be perceived as affecting the presentation of the faculty member. All conflicts of interest will be resolved prior to the start of the educational activity.
 
Michael Soderman, M.D., Ph.D. 
Financial relationships: None
Discussion of off-label, investigational or experimental drug use: None